Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opening Session Panel Discussion

Advertisement

Advertisement




Jan
03
Today In Oncology
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo